Misunderstanding in Clinical Research: Distinguishing Therapeutic Misconception, Therapeutic Misestimation, & Therapeutic Optimism
IRB Ethics and Human ResearchPublished 1 January 2003
Sam Horng, Christine Grady
Citations305
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
Abstract
Sam Horng, Christine Grady, Misunderstanding in Clinical Research: Distinguishing Therapeutic Misconception, Therapeutic Misestimation, & Therapeutic Optimism, IRB: Ethics & Human Research, Vol. 25, No. 1 (Jan. - Feb., 2003), pp. 11-16
Keywords
MedicineHealth Professions
JAMAWhat Makes Clinical Research Ethical?
2,561 Citations2000Ezekiel J. Emanuel
7 requirements are proposed that systematically elucidate a coherent framework for evaluating the ethics of clinical research studies and are universal, although they must be adapted to the health, economic, cultural, and technological conditions in which clinical research is conducted.
Journal of Legal MedicineA history and theory of informed consent
2,348 Citations1986Marshall B. Kapp
The Hastings Center ReportFalse Hopes and Best Data: Consent to Research and the Therapeutic Misconception
962 Citations1987Paul S. Appelbaum, Loren H. Roth +3 more
Appelbaum et al. suggest ways in which patients can be made to understand the differences between treatment and research, and the disadvantages and advantages of participation in the latter.
The LancetQuality of informed consent in cancer clinical trials: a cross-sectional survey
652 Citations2001Steven Joffe, E. Francis Cook +3 more
In multivariate analysis, increased knowledge was associated with college education, speaking only English at home, use of the US National Cancer Institute consent form template, not signing the consent form at initial discussion, presence of a nurse, and careful reading of the consent forms.
BMJExplaining risks: turning numerical data into meaningful pictures
641 Citations2002Adrian G. Edwards, Glyn Elwyn +1 more
ScienceCommunicating Statistical Information
638 Citations2000Ulrich Hoffrage, Samuel C. Lindsey +2 more
Hoffrage et al. demonstrate that these difficulties in understanding and combining statistical information effectively can be considerably reduced by communicating the information in terms of natural frequencies rather than in Terms of probabilities.
Journal of Clinical OncologyPerceptions of cancer patients and their physicians involved in phase I trials.
519 Citations1995Claire Daugherty, Mark J. Ratain +5 more
Cancer patients who participate in phase I trials appear to have an adequate self-perceived knowledge of the risks of investigational agents, however, only a minority of patients appear toHave an adequate understanding of the purpose of phase I Trials as dose-escalation/dose-determination studies.
JAMAUnderstanding patients' decisions. Cognitive and emotional perspectives
394 Citations1993Donald A. Redelmeier
The Journal of Law Medicine & EthicsDefining and Describing Benefit Appropriately in Clinical Trials
226 Citations2000Nancy M. P. King
Both low risks of great harm and high risks of small harm must be disclosed to prospective subjects and should be explained and categorized in ways that help potential subjects to understand and weigh them appropriately.
JAMAProfessional Integrity in Clinical Research
204 Citations1998Franklin G. Miller
This work examines critically 2 models of the moral identity of physician investigators, the investigator as clinician and the Investigator as scientist; in neither of these 2 models can the physician investigator eliminate completely the moral conflicts posed by clinical research.
Investigational New DrugsResponse rates, duration of response, and dose response effects in phase I studies of antineoplastics
157 Citations1991Daniel D. Von Hoff, Judith A. Turner
Although the response rate in phase I trials is indeed low, responses do occur and this response rate information should help the clinician provide facts for the patient considering a phase I trial with new anticancer agents.
IRB Ethics and Human ResearchQuantitative Analysis of Ethical Issues in Phase I Trials: A Survey Interview Study of 144 Advanced Cancer Patients
124 Citations2000Christopher K. Daugherty, Donald M. Banik +2 more
11. Ellis GB.
PubMedExpectations and experiences of patients with cancer participating in phase I clinical trials.
56 Citations1997Linda H. Yoder, Timothy J. O’Rourke +3 more
One theme that emerged from the data was hope/optimism, and findings support the importance of communication between the patient and family members and the healthcare team.
Acta OncologicaUnderstanding Informed Consent
53 Citations1999Ruth Macklin
The purpose of theinformed consent form is to document the informed consent discussion, and the place of informed consent in leading international codes of research ethics is reviewed.
Risk AnalysisDirect Inference, Probability, and a Conceptual Gulf in Risk Communication
18 Citations1995Vern R. Walker